Sai Life Sciences (SAILIFE) Q4 23/24 earnings summary

Executive summary

• Consolidated revenue from operations reached ₹14,651.78 million for FY 2023-24, up 20% year-over-year, with profit after tax at ₹828.09 million, a significant increase from ₹99.89 million in the previous year.

• Standalone revenue was ₹14,186.82 million, up 22% year-over-year, with profit after tax at ₹952.31 million, compared to ₹242.37 million last year.

• The company surpassed its vision of supporting 25 commercial molecules by 2025, achieving this milestone two years ahead of schedule.

Financial highlights

• Consolidated total income grew 19.97% year-over-year to ₹14,942.69 million.

• Standalone total income increased 22.15% year-over-year to ₹14,480.14 million.

• Consolidated profit after tax rose to ₹828.09 million from ₹99.89 million year-over-year.

• Standalone profit after tax increased to ₹952.31 million from ₹242.37 million year-over-year.

• No final dividend was recommended for FY 2023-24.

Outlook and guidance

• The company expects continued growth, driven by a strong pipeline of molecules at various clinical stages and ongoing investments in R&D and manufacturing capacity.

• Strategic focus remains on expanding global collaborations and enhancing sustainability initiatives.